Skip To Main Content
MSD Europe on Muck Rack

MSD Europe

As seen in: Lung Cancer, OncoDaily
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with MSD

Contact MSD, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

7th European Cancer Forum

|
By MSD Europe
| OncoDaily
The 7th edition of the European Cancer Forum (ECF) on December 4, 2025, will be held under the theme “Innovation, Security and Sustainability: Shaping the Future of Cancer Care,” aiming to ensure that advancements in oncology are not sidelined by the EU’s focus on external challenges.
Open in Who Shared Issue with article?

Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: a matching-adjusted indirect comparison

|
By Balazs Halmos, Thomas F. Burke, Chrysostomos Kalyvas, MSD Europe
| Lung Cancer Verified
Highlights • A matching-adjusted indirect comparison was conducted in 1st line nonsquamous NSCLC • Pembrolizumab + chemo and atezolizumab + chemo+/-bevacizumab were compared • OS and PFS were significantly better for pembrolizumab + chemo vs. atezolizumab + chemo • PFS was significantly better for pembrolizumab + chemo vs.
Open in Who Shared Issue with article?
See all 2 articles